Evidence map›Paper›PMID 40410588›Full record

ArticleNeuropsychopharmacology : official publication of the American College of Neuropsychopharmacology2025

Cortical myelin mapping in antipsychotic medication-naïve, first-episode psychosis patients.

Victoria L King, Gerhard Hellemann, Adrienne C Lahti, Matthew Defenderfer, Jill R Glausier, Hui Zhang, Nina V Kraguljac

Abstract read
In one paragraph

Article in Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. IncreasingBiological psychiatry global open science · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Victoria L KingDepartment of Psychology, University of Alabama at Birmingham, Birmingham, AL, USA.
Gerhard HellemannDepartment of Biostatistics, University of Alabama at Birmingham, Birmingham, AL, USA.
Adrienne C LahtiDepartment of Psychiatry and Behavioral Neurobiology, University of Alabama at Birmingham, Birmingham, AL, USA.
Matthew DefenderferResearch Computing, Information Technology, University of Alabama at Birmingham, Birmingham, AL, USA.
Jill R GlausierDepartment of Psychiatry, University of Pittsburgh, Pittsburgh, PA, USA.ORCID http://orcid.org/0000-0001-9838-3414
Hui ZhangCentre for Medical Image Computing, Department of Computer Science, University College London, London, UK.
Nina V KraguljacDepartment of Psychology, University of Alabama at Birmingham, Birmingham, AL, USA. nina.kraguljac@osumc.edu.ORCID http://orcid.org/0000-0003-2567-4098

Funding

Trajectories of treatment response as window into the heterogeneity of psychosis: a longitudinal multimodal imaging study in medication-naieve first episode psychosis patientsR01MH113800 · NIMH · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI LAHTI, ADRIENNE C · 2018 to 2022
$3.9M
Contribution of Glutamate Excess and Inflammation to Progressive White Matter Changes in PsychosisR01MH118484 · NIMH · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI KRAGULJAC, NINA VANESSA · 2019 to 2023
$3.3M
Glutamate, brain connectivity and duration of untreated psychosisR01MH102951 · NIMH · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI LAHTI, ADRIENNE C · 2014 to 2018
$2.9M
Treatment response in schizophrenia: bridging imaging and postmortem studiesR01MH081014 · NIMH · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI LAHTI, ADRIENNE C · 2009 to 2013
$1.8M
Structural and Neurometabolic White Matter Integrity in the Deficit SyndromeK23MH106683 · NIMH · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI KRAGULJAC, NINA VANESSA · 2015 to 2019
$883k
NIMH NIH HHS K23 MH106683NIMH NIH HHS R01 MH081014NIMH NIH HHS R01 MH102951NIMH NIH HHS R01 MH113800NIMH NIH HHS R01 MH118484U.S. Department of Health & Human Services | NIH | National Institute of Mental Health (NIMH) K23MH06683U.S. Department of Health & Human Services | NIH | National Institute of Mental Health (NIMH) R01MH081014U.S. Department of Health & Human Services | NIH | National Institute of Mental Health (NIMH) R01MH102951U.S. Department of Health & Human Services | NIH | National Institute of Mental Health (NIMH) R01MH113800U.S. Department of Health & Human Services | NIH | National Institute of Mental Health (NIMH) R01MH118484
6 · The paper itself

Abstract

While white matter myelin primarily functions to accelerate conduction velocity and has been extensively studied in schizophrenia-spectrum disorders (SSD), less is known about the role of gray matter myelin in SSD. Cortical myelination occurs mostly on the proximal axons of parvalbumin positive (PV+) interneurons, where it assists in trophic support and experience-dependent plasticity. Given the role of PV+ interneuron dysfunction in SSD, it is critical to advance our understanding of cortical myelin pathology in this context. Here, we quantified myelin maps using the T1w/T2w ratio in a large group of antipsychotic medication-naïve, first-episode psychosis patients. We compared myelin content between patients (N = 91) and controls (N = 107) using a MANCOVA and calculated zero-order correlations with the discriminant function for each region, then used a machine learning approach to identify the most parsimonious constellation of cortical regions driving group differences using a stepwise algorithm. Group membership was significantly associated with T1w/T2w ratio (Wilks Lambda = 0.09, p < 0.01), where patients had higher myelin values compared to healthy controls. We identified a subset of 16 regions, primarily located in association cortices, that were sufficient to explain group differences. Here, we report an increase in the cortical T1w/T2w ratio in association cortices in first-episode psychosis. We suggest that faulty myelin compaction during this critical developmental period could contribute to PV+ interneuron pathology and cortical microcircuit disruptions resulting in the clinical phenotype. With additional empirical support from future studies, novel treatment strategies targeting cortical myelin could have potential to mitigate circuit dysfunction in the illness.

Indexed as

Cerebral CortexMyelin SheathPsychotic DisordersAdolescentAdultBrain MappingFemaleHumansMagnetic Resonance ImagingMaleYoung Adult

Identifiers

PMID40410588
PMCPMC12260055

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.